Blue Wave Therapeutics GmbH

Blue Wave Therapeutics is developing a novel radiopharmaceutical platform to address cancers with high unmet medical need, initially focusing on glioblastoma. Its lead candidate, ARAspheres, consists of integrin-targeting alginate microparticles loaded with the alpha-emitting radionuclide Actinium-225, designed for local administration into the tumor resection cavity. This approach enables highly potent and localized tumor cell killing while minimizing systemic exposure. The company aims to advance ARAspheres to clinical Proof of Concept and pursue an M&A exit with a biopharma partner for further development and commercialization.